Pfizer

NYSE: PFE
$33.83
+$0.37 (+1.1%)
Closing price July 10, 2020
24/7 Wall St. has identified five defensive stocks that must greatly improve before they are deemed expensive or fully valued again.
Pfizer is among the current frontrunners for a COVID-19 vaccine, so why is its stock down 13% year to date? And why does one independent research firm say this stock could run much higher?
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
As of the most recently reported period, short sellers favored Exxon, Pfizer and Microsoft above all other Dow stocks.
As of the most recently reported period, short sellers favored Exxon, Pfizer and Microsoft above all other Dow stocks. The overall trend of shrinking short interest continued.
BioNTech and Pfizer stocks each made a handy gain on Monday after the companies announced the beginning of human trials for a COVID-19 vaccine.
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday. Although markets appear to be recovering, investors were not thrilled about this quarter for these two...
Pharmaceutical giants Merck and Pfizer are expected to report their most recent quarterly results before the opening bell Tuesday.
The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers favored Exxon, Microsoft and Pfizer above all other Dow stocks.
Over one-third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week. Here's what to expect.
BioNTech shares shot up on Wednesday after the company announced, in conjunction with Pfizer, that its COVID-19 vaccine program was approved in Germany.